Hoth Therapeutics (NASDAQ:HOTH) Posts Earnings Results, Misses Expectations By $0.01 EPS

Hoth Therapeutics (NASDAQ:HOTH) issued its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01), Zacks reports.

Hoth Therapeutics Price Performance

HOTH traded down $0.05 during trading hours on Friday, reaching $0.80. The company’s stock had a trading volume of 140,312 shares, compared to its average volume of 1,389,181. Hoth Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $1.73. The stock has a market cap of $5.51 million, a PE ratio of -0.59 and a beta of 0.84. The business’s 50-day moving average is $0.92 and its 200-day moving average is $0.93.

Analyst Ratings Changes

A number of analysts have recently issued reports on HOTH shares. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a research note on Monday, November 4th. EF Hutton Acquisition Co. I raised Hoth Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 21st. Finally, Benchmark reiterated a “speculative buy” rating and set a $3.00 price target on shares of Hoth Therapeutics in a report on Friday, October 11th.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.